Trillium Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, TRIL, Trillium Therapeutics Inc, priceseries

Trillium Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
18.44
Close
18.44
High
18.44
Low
18.44
Previous Close
18.44
Daily Price Gain
0.00
YTD High
18.49
YTD High Date
Nov 16, 2021
YTD Low
5.80
YTD Low Date
Aug 20, 2021
YTD Price Change
4.29
YTD Gain
30.32%
52 Week High
18.49
52 Week High Date
Nov 16, 2021
52 Week Low
5.80
52 Week Low Date
Aug 20, 2021
52 Week Price Change
6.32
52 Week Gain
52.15%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 2. 2017
5.35
Feb 22. 2017
6.09
13 Trading Days
13.78%
Link
LONG
Oct 5. 2017
5.20
Nov 9. 2017
8.52
25 Trading Days
63.79%
Link
LONG
Nov 17. 2017
9.55
Dec 1. 2017
10.60
9 Trading Days
11.03%
Link
LONG
Aug 22. 2018
5.20
Sep 10. 2018
5.72
12 Trading Days
9.94%
Link
LONG
Dec 9. 2019
0.32
Jan 31. 2020
3.87
36 Trading Days
1124.56%
Link
LONG
Feb 28. 2020
5.05
Mar 9. 2020
5.59
6 Trading Days
10.74%
Link
LONG
May 1. 2020
4.71
May 22. 2020
6.44
15 Trading Days
36.79%
Link
LONG
Aug 11. 2020
8.33
Sep 2. 2020
10.38
16 Trading Days
24.67%
Link
LONG
Dec 29. 2020
13.01
Jan 11. 2021
14.36
8 Trading Days
10.34%
Link
Company Information
Stock Symbol
TRIL
Exchange
NasdaqCM
Company URL
http://www.trilliumtherapeutics.com
Company Phone
(416) 595-0627
CEO
Niclas Stiernholm
Headquarters
Ontario
Business Address
2488 DUNWIN DRIVE, MISSISSAUGA, CANADA L5L 1J9
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001616212
About

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its lead program, SIRPaFc, is an antibody-like fusion protein that blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system. The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.

Description

Trillium Therapeutics Inc., a biopharmaceutical development company, advances cancer stem cell discoveries into novel and cancer therapies in Canada. Its products comprise Tigecycline, an antibiotic, which is in phase I for study in patients with relapsed or refractory acute myeloid leukemia (AML); SIRPaFc, an antibody-like fusion protein, which is in pre-clinical stage that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and other tumors; CD200, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule; and TTI-1612, a recombinant soluble for the treatment of interstitial cystitis (IC), a chronic bladder disease characterized by low urinary HB-EGF levels and a dysfunctional, which recently completed a 28-patient Phase I trial in IC patients. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading